Meta-analysis results for all treatments

Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE). method

Treament Trials      
clinical deteriorationclinical improvementdeathsviral clearance
chloroquine and derivatives41 1.15 [0.92; 1.43], 6 RCTs, I2=2%
inconclusive result
1.20 [0.85; 1.70], 4 RCTs, I2=34%
inconclusive result
1.08 [0.98; 1.19], 25 RCTs, I2=0%
inconclusive result
0.83 [0.57; 1.21], 2 RCTs, I2=0%
inconclusive result
ivermectin22 0.47 [0.28; 0.79], 4 RCTs, I2=0%
low degree of certainty
1.67 [1.05; 2.66], 3 RCTs, I2=0%
low degree of certainty
0.26 [0.13; 0.50], 7 RCTs, I2=8%
low degree of certainty
0.92 [0.77; 1.09], 1 RCT, I2=0%
inconclusive result
favipiravir 14- 1.36 [0.88; 2.09], 5 RCTs, I2=35%
inconclusive result
0.78 [0.28; 2.22], 5 RCTs, I2=0%
inconclusive result
1.64 [1.10; 2.44], 7 RCTs, I2=56%
low degree of certainty
hydroxychloroquine plus macrolides8 0.99 [0.57; 1.72], 1 RCT, I2=0%
inconclusive result
- 0.72 [0.22; 2.41], 2 RCTs, I2=0%
inconclusive result
-
Renin-angiotensin-system-acting agents8 OBS 0.93 [0.64; 1.36], 4 studies, I2=3%
inconclusive result
- 0.92 [0.47; 1.77], 2 RCTs, I2=0%
inconclusive result
-
azithromycin6 1.26 [0.93; 1.70], 2 RCTs, I2=0%
inconclusive result
- 1.03 [0.87; 1.21], 4 RCTs, I2=13%
inconclusive result
OBS 715.00 [12.94; 39513.71], 1 study, I2=0%
unassessable degree of certainty
lopinavir/ritonavir6 3.69 [0.37; 36.57], 1 RCT, I2=0%
inconclusive result
1.72 [0.98; 3.01], 3 RCTs, I2=64%
inconclusive result
1.01 [0.91; 1.13], 7 RCTs, I2=0%
inconclusive result
3.24 [1.15; 9.10], 2 RCTs, I2=24% demonstrated
moderate degree of certainty
remdesivir6- 1.24 [1.13; 1.36], 5 RCTs, I2=0% demonstrated
moderate degree of certainty
0.72 [0.56; 0.94], 6 RCTs, I2=0%
moderate degree of certainty
-
umifenovir (arbidol)4 0.86 [0.06; 11.36], 1 RCT, I2=0%
inconclusive result
OBS 0.75 [0.47; 1.20], 1 study, I2=0%
inconclusive result
1.00 [0.18; 5.59], 2 RCTs, I2=0%
inconclusive result
2.80 [0.31; 25.53], 1 RCT, I2=0%
inconclusive result
doxycycline2 0.44 [0.24; 0.78], 2 RCTs, I2=0%
low degree of certainty
1.89 [1.06; 3.38], 1 RCT, I2=0%
low degree of certainty
0.39 [0.11; 1.42], 2 RCTs, I2=0%
inconclusive result
-
sofosbuvir and daclatasvir2-- 0.47 [0.15; 1.46], 2 RCTs, I2=0%
inconclusive result
-
azvudine1----
baloxavir marboxil1-- 1.00 [0.02; 55.80], 1 RCT, I2=0%
inconclusive result
-
lopinavir/ritonavir, ribavirin and interferon beta-1b1- 3.92 [1.66; 9.24], 1 RCT, I2=0%
moderate degree of certainty
0.47 [0.01; 24.30], 1 RCT, I2=0%
inconclusive result
4.37 [1.86; 10.25], 1 RCT, I2=0% demonstrated
moderate degree of certainty
oseltamivir1- OBS 0.76 [0.42; 1.37], 1 study, I2=0%
inconclusive result
0.51 [0.04; 6.12], 1 RCT, I2=0%
inconclusive result
OBS 1.03 [0.57; 1.87], 1 study, I2=0%
inconclusive result
ASC09/ritonavir0----
carrimycin0----
danoprevir / ritonavir0----
darunavir cobicistat0----
darunavir/cobicistat plus chloroquine0----
fluvoxamine0----
leronlimab0----
lopinavir / ritonavir plus ribavirin0----
lopinavir/ritonavir plus chloroquine0----
lopinavir/ritonavir plus interferon ß-1a0----
meplazumab0----
nitazoxanide0----
oseltamivir plus chloroquin0----
ribavirin0----
ritonavir0----
tenofovir/emtricitabine0----
tenofovir/emtricitabine plus hydroxychloroquine0----
tranexamic acid0----
triazavirin0----